FY2027 EPS Estimates for AC Immune Cut by HC Wainwright

AC Immune SA (NASDAQ:ACIU) – Analysts at HC Wainwright cut their FY2027 earnings estimates for AC Immune in a research report issued to clients and investors on Thursday, May 1st. HC Wainwright analyst A. Fein now expects that the company will earn $0.12 per share for the year, down from their previous estimate of $0.16. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune’s FY2028 earnings at $1.29 EPS and FY2029 earnings at $1.89 EPS.

AC Immune Stock Up 3.0 %

Shares of NASDAQ:ACIU opened at $1.72 on Friday. The stock has a market cap of $172.71 million, a price-to-earnings ratio of -3.74 and a beta of 1.62. The business’s 50 day moving average is $1.92 and its 200 day moving average is $2.57. AC Immune has a 12-month low of $1.43 and a 12-month high of $4.98.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $1.12 million during the quarter, compared to the consensus estimate of $1.99 million.

Institutional Trading of AC Immune

Several institutional investors have recently made changes to their positions in the company. Quinn Opportunity Partners LLC bought a new position in shares of AC Immune in the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP purchased a new stake in AC Immune during the fourth quarter worth about $36,000. Boothbay Fund Management LLC purchased a new position in AC Immune in the fourth quarter valued at approximately $38,000. RPO LLC purchased a new position in shares of AC Immune during the 4th quarter valued at $51,000. Finally, Jane Street Group LLC purchased a new position in shares of AC Immune in the fourth quarter worth about $66,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.